Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021

Rhea-AI Summary

Aurinia Pharmaceuticals will release its Q1 2021 financial results on May 6, 2021, after market closure. A conference call is scheduled for the same day at 5:00 p.m. EDT to discuss the results and provide a business update. The call can be accessed via dial-in or through an audio webcast available on the company's website. Aurinia focuses on serious diseases, having introduced LUPKYNIS™, the first FDA-approved oral therapy for adult patients with active lupus nephritis.

Positive

• Aurinia's LUPKYNIS™ is the first FDA-approved oral therapy for active lupus nephritis, indicating a strong market position.
• The upcoming financial results and conference call may provide insights into the company's growth strategies.

Negative

• None.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its first quarter 2021 financial results on Thursday, May 6, 2021, after the markets close. Aurinia’s management team will also host a conference call at 5:00 p.m. EDT to discuss the Company’s financial results and to provide a general business update.

The conference call and webcast is scheduled for May 6, 2021 at 5:00 p.m. ET. In order to participate in the conference call, please dial +1-888-506-0062 (toll-free U.S.) or +1-973-528-0011 (international); entry code: 662377. The audio webcast can be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will also be available on Aurinia’s website approximately two hours after the live call is completed.

ABOUT AURINIA

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005151/en/

FAQ

When will Aurinia Pharmaceuticals announce its first quarter 2021 financial results?

Aurinia Pharmaceuticals will announce its first quarter 2021 financial results on May 6, 2021, after market close.

What time is Aurinia's conference call scheduled for?

The conference call is scheduled for May 6, 2021, at 5:00 p.m. EDT.

How can I access the Aurinia Pharmaceuticals conference call?

You can access the conference call by dialing +1-888-506-0062 (toll-free) or +1-973-528-0011 (international) or via the audio webcast on Aurinia's corporate website.

What is LUPKYNIS™ and its significance for Aurinia Pharmaceuticals?

LUPKYNIS™ is the first FDA-approved oral therapy for adult patients with active lupus nephritis, marking a significant advancement for Aurinia in targeted therapies.